Pharmaron Beijing Co., Ltd. announced that its operating revenue for the first three quarters of 2026 reached 12.003 billion yuan, a year-on-year increase of 19.01%. Net profit attributable to the parent company was 1.247 billion yuan, up 9.31% year-on-year, and non-IFRS net profit was 1.181 billion yuan, a year-on-year increase of 14.20%. For the third quarter alone, operating revenue was 4.408 billion yuan, up 20.94% year-on-year; net profit attributable to the parent company was 497 million yuan, up 13.06% year-on-year; and non-IFRS net profit was 488 million yuan, a year-on-year increase of 22.74%.